Multimarker risk stratification approach at multiple sclerosis onset.

[1]  A. Casrouge,et al.  Inhibition of DPP4 activity in humans establishes its in vivo role in CXCL10 post‐translational modification: prospective placebo‐controlled clinical studies , 2016, EMBO molecular medicine.

[2]  H. Masur,et al.  Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy , 2015, PloS one.

[3]  A. Casrouge,et al.  Plasma Biomarkers Discriminate Clinical Forms of Multiple Sclerosis , 2015, PloS one.

[4]  A. Minagar,et al.  IL1-β expression in multiple sclerosis , 2014, Journal of the Neurological Sciences.

[5]  A. Casrouge,et al.  Low DPP4 expression and activity in multiple sclerosis. , 2014, Clinical immunology.

[6]  R. Shakir,et al.  The classification of neurological disorders in the 11th revision of the International Classification of Diseases (ICD-11) , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[7]  Yiqian Chen,et al.  Advances in Understanding the Expression and Function of Dipeptidyl Peptidase 8 and 9 , 2013, Molecular Cancer Research.

[8]  F. Fazekas,et al.  Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis , 2013, Multiple sclerosis.

[9]  H. Lassmann,et al.  Expression of Ccl11 Associates with Immune Response Modulation and Protection against Neuroinflammation in Rats , 2012, PloS one.

[10]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of Neurology.

[11]  E. Celius,et al.  Genetic variants of CC chemokine genes in experimental autoimmune encephalomyelitis, multiple sclerosis and rheumatoid arthritis , 2010, Genes and Immunity.

[12]  P. Proost,et al.  Citrullination of CXCL10 and CXCL11 by peptidylarginine deiminase: a naturally occurring posttranslational modification of chemokines and new dimension of immunoregulation. , 2008, Blood.

[13]  Joav Merrick,et al.  Neurological Disorders: Public Health Challenges , 2007 .

[14]  T. Gallart,et al.  CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Antel,et al.  Pathogenesis of multiple sclerosis , 2005, Current opinion in neurology.

[16]  C. Matute,et al.  Multiple sclerosis: novel perspectives on newly forming lesions , 2005, Trends in Neurosciences.

[17]  M. Buttmann,et al.  Interferon-β induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis , 2004, Journal of Neuroimmunology.

[18]  M. Barnett,et al.  Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion , 2004, Annals of neurology.

[19]  S. Husson,et al.  Carboxyterminal cleavage of the chemokines MIG and IP-10 by gelatinase B and neutrophil collagenase. , 2003, Biochemical and biophysical research communications.

[20]  M. Filippi,et al.  Inflammation in multiple sclerosis: the good, the bad, and the complex , 2002, The Lancet Neurology.

[21]  M. Parmentier,et al.  Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. , 2001, Blood.

[22]  E. Bosmans,et al.  Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. , 2000, European journal of biochemistry.

[23]  I. De Meester,et al.  CD26, let it cut or cut it down. , 1999, Immunology today.

[24]  V. Perry,et al.  Axonal damage in acute multiple sclerosis lesions. , 1997, Brain : a journal of neurology.

[25]  C. Brosnan,et al.  Cytokine localization in multiple sclerosis lesions , 1995, Neurology.

[26]  T. Owens,et al.  The immunology of multiple sclerosis and its animal model, experimental allergic encephalomyelitis. , 1995, Neurologic clinics.

[27]  C. Morimoto,et al.  Cell surface modulation of CD26 by anti-1F7 monoclonal antibody. Analysis of surface expression and human T cell activation. , 1990, Journal of immunology.

[28]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[29]  S. Sánchez-Ramón,et al.  Close Encounters of the First Kind: Innate Sensors and Multiple Sclerosis , 2015, Molecular Neurobiology.

[30]  D. Willenborg,et al.  Cytokines in the pathogenesis and therapy of autoimmune encephalomyelitis and multiple sclerosis. , 2003, Advances in experimental medicine and biology.

[31]  D. Marguet,et al.  Dipeptidyl peptidase IV/CD26 in T cell activation, cytokine secretion and immunoglobulin production. , 2003, Advances in experimental medicine and biology.

[32]  Interleukin-1 (cid:98) is Required for the Early Evolution of Reactive Astrogliosis Following CNS Lesion , 2022 .